Clinical Trial Update: Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated zolpidem (Ambien) for ADHD-associated insomnia in children aged 6 to 17, assessing efficacy, safety, and tolerability. The study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Insomnia

Drugs mentioned

• Ambien (zolpidem)

Snippet

Sponsor: Sanofi | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED